Leading Dermatologic Associations and Skin Cancer Prevention Organizations Urge U.S. Surgeon General to Renew Skin Cancer Call to Action
September 18, 2024 12:46 ET
|
American Society for Dermatologic Surgery Association
Schaumburg, Ill., Sept. 18, 2024 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery Association (ASDSA), in conjunction with the American Academy of Dermatology Association (AAD), the...
ASDS Experts Share Procedural Dermatology Techniques at Unique Hands-on Course With Innovative 3D Technology
September 16, 2024 07:00 ET
|
American Society for Dermatologic Surgery
Schaumburg, IL, Sept. 16, 2024 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery (ASDS) welcomed more than 50 dermatologic surgeons and dermatology residents to its new course, “ASDS...
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
September 11, 2024 01:04 ET
|
Regeneron Pharmaceuticals, Inc.
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in...
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
September 11, 2024 00:59 ET
|
Regeneron Pharmaceuticals, Inc.
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is...
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
September 09, 2024 10:20 ET
|
Spherix Global Insights
EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market....
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
September 09, 2024 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
U.S. Dermatology Imaging Devices Market Report 2024-2030: Digital Photographic Imaging, OCT, Dermatoscope, Skin Cancers, Inflammatory Dermatoses Size, Share & Trends Analysis
September 09, 2024 07:34 ET
|
Research and Markets
Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "U.S. Dermatology Imaging Devices Market Size, Share & Trends Analysis Report By Modality (Digital Photographic Imaging, OCT, Dermatoscope), By...
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 08:15 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan
August 22, 2024 09:00 ET
|
Inhibitor Therapeutics, Inc.
TAMPA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) today provided an update on development efforts for its itraconazole formulation for the...
Honoring the Legacy of Dr. Alastair Carruthers
August 21, 2024 18:11 ET
|
American Society for Dermatologic Surgery
Schaumburg, IL, Aug. 21, 2024 (GLOBE NEWSWIRE) -- It is with deep sorrow that the American Society for Dermatologic Surgery (ASDS) announces the passing of Alastair Carruthers, FRCPC, a pioneering...